Catechol-containing compound catabolic process

Across TCGA pan-cancer cohorts, RNA activity of the Catechol-containing compound catabolic process pathway differs between tumor and matched normal tissue in 15 of the 18 cancer types tested.

The strongest signal is observed in lung adenocarcinoma (LUAD), where pathway activity is lower in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as LUAD and STAD, show the opposite pattern, with lower activity in tumor tissue.

LUAD, STAD, and BLCA show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log₂ scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.

Lineage	Gender	Stage	Activity change	p	Sampling consensus
LUAD	All	II,III,IV	−0.096	<.001	10	view →
STAD	All	II,III,IV	−0.165	<.001	9	view →
BLCA	All	All	−0.109	<.001	9	view →
HNSC	Male	II,III,IV	−0.112	<.001	8	view →
BRCA	All	III,IV	−0.204	<.001	6	view →
UCEC	All	All	−0.199	<.001	6	view →
KICH	Male	All	−0.191	<.001	6	view →
LUSC	Male	II,III,IV	−0.170	<.001	6	view →
LIHC	Female	All	−0.103	<.001	6	view →
THCA	All	All	+0.068	<.001	5	view →
COAD	All	All	−0.046	.006	4	view →
ESCA	All	All	−0.206	<.001	3	view →

Pink = more active in tumor, green = less active in tumor. Showing the 12 strongest of 15 lineages.

GO:0019614–LUAD

Open the LUAD breakdown →